Serial No.: 10/002,211 Attorney Docket No.: IMMU:003US1

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application: Claims 1-77. canceled.

- 78. (Currently amended) A method of ablating normal cells in a subject, comprising parenterally administering to a subject a therapeutically effective amount of a sterile injectable composition comprising a B-cell antibody or fragment thereof, which specifically binds to a B-cell, in a pharmaceutically acceptable injection vehicle, thereby to ablate the normal cells.
- 79. (Previously presented) A method according to claim 78, wherein the subject has been diagnosed with immune thrombocytopenic purpura.
- 80. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is a Fv, single chain antibody, Fab, Fab', or F(ab')₂ fragment.
- 81. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is an intact antibody.
- 82. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is conjugated to a therapeutic agent.
- 83. (Previously presented) A method according to claim 82, wherein the therapeutic agent is a cytotoxic agent.
- 84. (Previously presented) A method according to claim 83, wherein the cytotoxic agent is a therapeutic radioisotope.
- 85. (Previously presented) A method according to claim 82, wherein the therapeutic agent is a drug.
- 86. (Previously presented) A method according to claim 82, wherein the therapeutic agent is a toxin.

87-92. Canceled.

93. (Currently amended) A method of ablating normal cells in a subject, comprising parenterally administering to a subject a therapeutically effective amount of a sterile injectable composition comprising a B-cell antibody or fragment thereof, which specifically binds to a B-cell, in a pharmaceutically acceptable injection vehicle, wherein the antibody or fragment thereof is a polyclonal, chimeric or hybrid antibody which binds multiple epitopes or antigens, thereby to ablate the normal cells.

Serial No.: 10/002,211 Attorney Docket No.: IMMU:003US1

94. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is a human monoclonal antibody.

- 95. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is a mouse/human chimeric monoclonal antibody.
- 96. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is a genetically engineered antibody.
- 97. (Previously presented) A method according to claim 93, wherein the antibody or antibody fragment is conjugated to a therapeutic agent.
- 98. (Previously presented) A method according to claim 97, wherein the antibody or antibody fragment is conjugated to a cytotoxic agent.
- 99. (Previously presented) A method according to claim 93, wherein the antibody or antibody fragment is conjugated to a drug.
- 100. (Previously presented) A method according to claim 93, wherein the antibody or antibody fragment is conjugated to a radioisotope.
- 101. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is conjugated to a cytokine.
- 102. (Previously presented) A method of treating an immune disease in a subject according to claim 78, wherein said immune disease is a B-cell immune disease.
- 103. (Previously presented) A method of treating an immune disease in a subject according to claim 78, wherein said antibody or antibody fragment is a B-cell antibody.
- 104. (Currently amended) A method of treating an immune disease in a subject, comprising parenterally administering to a subject that has been diagnosed with an immune disease a therapeutically effective amount of a sterile injectable composition consisting of a B-cell antibody or fragment thereof, which specifically binds to a B-cell, in a pharmaceutically acceptable injection vehicle, whereby the immune disease is treated.
- 105. (Previously presented) A method of treating an immune disease in a subject according to claim 104, wherein said immune disease is a B-cell immune disease.
- 106. (Previously presented) A method according to claim 93, wherein the subject has been diagnosed with immune thrombocytopenic purpura.

Serial No.: 10/002,211 Attorney Docket No.: IMMU:003US1

107. (Previously presented) A method according to claim 93, wherein the antibody or antibody fragment is an intact antibody.

- 108. (Previously presented) A method according to claim 93, wherein the antibody or antibody fragment is conjugated to a therapeutic agent.
- 109. (Previously presented) A method according to claim 78, wherein the normal cells are normal spleen cells.
- 110. (Previously presented) A method according to claim 109, wherein the normal spleen cells are B cells.
- 111. (Previously presented) A method according to claim 109, wherein the antibody is directed against normal and malignant B-cells, and wherein the method is used to treat normal spleen cells in said subject.
- 112. (Previously presented) A method according to claim 111, wherein the normal spleen cells are B cells.
- 113. (Previously presented) A method according to claim 112, wherein said subject has been diagnosed with an immune disease.
- 114. (New) A method according to claim 78, wherein the antibody is specific to a marker associated with a B cell.
- 115. (New) A method according to claim 112, wherein the antibody is specific to a marker associated with a B cell.
- 116. (New) A method according to claim 104, wherein the antibody is specific to a marker associated with a B cell.